https://www.thebodypro.com/category/raltegravir-isentress-mk0518/tag/international-aids-conference
Raltegravir (Isentress)

International AIDS Conference

The Latest

Raltegravir-Based Third-Line ART in Children and Adolescents Img

Raltegravir-Based Third-Line ART in Children and Adolescents

Five case studies from Uganda showed good responses in children and adolescents receiving raltegravir-based third-line ART.

Raltegravir in HIV-Exposed Neonates Img

Raltegravir in HIV-Exposed Neonates

Daily raltegravir was well tolerated and met pharmacokinetic targets in full term HIV-exposed infants at high risk of infection, in a study presented at the 8th International Workshop on HIV Paediatrics.

Once-Daily Raltegravir and Dolutegravir-Based Dual-Drug Regimen Show Promise Img

Once-Daily Raltegravir and Dolutegravir-Based Dual-Drug Regimen Show Promise

On behalf of IFARA, Fred Schaich spoke with Pedro Cahn, M.D., Ph.D., about two late-breaking studies presented at this year's International AIDS Conference and about global funding for HIV.

Once-Daily Raltegravir at Last Available: Week 48 Results From ONCEMRK Study Img

Once-Daily Raltegravir at Last Available: Week 48 Results From ONCEMRK Study

After many years of research, Merck now have a once-daily formulation of raltegravir -- though it requires two tablets with a higher milligram dose.

Promo Image

Five-Year Results From Raltegravir Registrational Studies

Two posters at IAS included five-year results from the phase 3 registrational studies of raltegravir.

A late breaker poster detailed the final five year results of the phase 3 placebo-controlled registrational study comparing raltegravir to efaviren...

Promo Image

Elvitegravir vs. Raltegravir: 96-Week Phase III Results in Treatment-Experienced Patients

Richard Elion from Whitman-Walker Health in Washington presented updated 96 week results from the phase 3 head-to-head study of elvitegravir vs raltegravir.1

The 48 week results, first presented at the IAS conference in Rome last year showed elviteg...

Promo Image

Dolutegravir vs. Raltegravir in Treatment-Naive Patients: 48-Week Results From the SPRING 2 Study

Francois Raffi, from University of Nantes, France, presented the SPRING-2 study as an oral late breaker.

This was a randomised, double-blind, double-placebo controlled, non-inferiority study in treatment-naive patients. Participants (from Canada, U....

Promo Image

Raltegravir Lovefest, Vienna Edition: AIDS 2010 Studies Explore Various Strategies for Use -- A Blog Entry by Myles Helfand

Myles is the editorial director of TheBody.com and TheBodyPRO.com.

The first set of scientific presentations at AIDS 2010 brought us some new research on raltegravir (Isentress), a study on raltegravir and some new data on ... let me see here ... ah...

Promo Image

Potent Antiretroviral Effect Seen With the Integrase Inhibitor MK-0518 as Part of Combination ART in Treatment-Naive, HIV-1-Infected Patients

Integrase is an HIV enzyme that allows the HIV virus to insert its genetic material into the DNA of human T cells. HIV integrase inhibition is a new mechanism of viral inhibition that blocks this step in the life cycle of HIV, thus preventing HIV fro...